BioCryst Pharmaceuticals logo

BioCryst Pharmaceuticals

BCRX | NASDAQ
Chart Builder DCF Calculator
$7.45
-$0.16 (-2.10%)
At close: Nov 16, 2026, 4:00 PM ET
$7.64
+$0.19 (+2.58%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.10%

Rating

Updated: Nov 14, 2026
49
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #295/1021 (Top 29%)

Key Statistics

Market Data

Market Cap $1.92B
1D Range
7.41 7.74
52W Range
6.24 11.11

Valuation (TTM)

PE -5.25
PB -4.82
EV/EBITDA -8.31

Valuation (NTM)

Forward PE 14.71
Forward PEG 0.00
Price Target $17.00
Loading financial charts...

Profile

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products:...

Sector Healthcare
Industry Biotechnology
Employees 435
IPO Date Mar 4, 1994
Fiscal Year January - December

Latest News

BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting

3 days ago · globenewswire.com

BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth

6 days ago · zacks.com

4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript
BioCryst Pharmaceuticals Q3 Earnings Call Highlights

13 days ago · marketbeat.com

BioCryst Pharmaceuticals Q3 Earnings Call Highlights
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates

13 days ago · zacks.com

BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates
BioCryst Reports Third Quarter 2026 Financial Results

13 days ago · globenewswire.com

BioCryst Reports Third Quarter 2026 Financial Results
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

18 days ago · zacks.com

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

20 days ago · zacks.com

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BioCryst to Report Third Quarter 2026 Financial Results on November 4

26 days ago · globenewswire.com

BioCryst to Report Third Quarter 2026 Financial Results on November 4
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

1 month ago · globenewswire.com

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

Earnings

Latest Earnings
Nov 4, 2026
EPS
$0.14
Beat +52.41%
REV
$180.29M
Beat +8.83%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$17.00
Upside
+128.19%
Buy (5)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.